Comparison 5. Alfacalcidol [1‐alpha(OH)D3] versus control or placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
5.1 Persons sustaining new non‐vertebral fracture	3	526	Risk Ratio (M‐H, Fixed, 95% CI)	0.97 [0.25, 3.82]
5.1.1 Not selected on the basis of previous osteoporotic fracture	1	380	Risk Ratio (M‐H, Fixed, 95% CI)	0.97 [0.25, 3.82]
5.1.2 Selected on the basis of previous osteoporotic fracture	2	146	Risk Ratio (M‐H, Fixed, 95% CI)	Not estimable
5.2 Persons sustaining new vertebral fracture	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
5.2.1 Selected on the basis of previous osteoporotic fracture	1	740	Risk Ratio (M‐H, Fixed, 95% CI)	0.56 [0.48, 0.65]